Novavax shares rise 1.18% premarket after issuing $225m in convertible bonds.

Novavax, Inc. rose 1.18% in premarket trading, with the company issuing $225 million in convertible bonds due in 2031. This move is part of Novavax's strategy to raise capital for its vaccine development programs, including its COVID-19 vaccine and other vaccine candidates. The company's differentiated vaccine platform, which combines recombinant protein technology and advanced nanoparticle technology, is expected to enhance the immune response and drive future growth.